Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer.

International journal of biological macromolecules - 31 Jan 2021

Zhao Yuping, Bilal Muhammad, Raza Ali, Khan Muhammad Imran, Mehmood Shahid, Hayat Uzma, Hassan Sherif T S, Iqbal Hafiz M N

Abstract excerpt

Cancer is one of the leading causes of death with a mortality rate of 12%. Although significant progress has been achieved in cancer research, the effective treatment of cancer remains the greatest global challenge in medicine. Dysregulation of tyrosine kinases (TK) is one of the characteristics of several types of cancers. Thus, drugs that target and inhibit these enzymes, known as TK inhibitors (TKIs), are...

Topics

Join the communities discussing this publication.

Antineoplastic Agents
Drug Delivery Systems
Drug Resistance, Neoplasm
Molecular Targeted Therapy
Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Protein Kinase Inhibitors

Protein-Tyrosine Kinases

Signal Transduction

Source

Identifiers

PMID: 33290765
DOI: 10.1016/j.ijbiomac.2020.12.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer.PMID 33290765Read ↗

A New Challenging and Promising Era of Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Synthetic and Naturally Occurring Heterocyclic Anticancer Compounds with Multiple Biological TargetsSemantic proximity Read ↗

Recent Advances in Boosting EGFR Tyrosine Kinase Inhibitors-Based Cancer Therapy.Semantic proximity Read ↗

Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and ChallengesSemantic proximity Read ↗

Protein Kinases as Targets for Cancer TreatmentSemantic proximity Read ↗

Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspectiveSemantic proximity Read ↗

Kinase-targeted cancer therapies: progress, challenges and future directionsSemantic proximity Read ↗

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future PerspectivesSemantic proximity Read ↗

Kinase Inhibitors in Multitargeted Cancer TherapySemantic proximity Read ↗

Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancerSemantic proximity Read ↗

Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insightsSemantic proximity Read ↗

Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.